Tradestie Institutional Equity Comparison Engine
SRZN vs MTNB โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
SRZN Overall Edge
SRZN Captures Institutional Edge (3โ0 Pillars ยท 5โ2 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Surrozen, Inc. Common (SRZN) driven by superior Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, SRZN trades at N/M Forward P/E with -485.4% operating margin (+408.6% YoY revenue) versus MTNB at N/M Forward P/E and 0.0% operating margin (-100.0% YoY). In options structure, SRZN sits in CONSOLIDATION (13th %ile IV; Dealer Gamma Walls on Pro) against MTNB sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).
Valuation Winner
Tie
SRZN N/M vs MTNB N/M Fwd P/E
Growth & Margin Winner
SRZN
Op Margin -485.4% vs 0.0% ยท YoY +408.6% vs -100.0%
Momentum & Technical Winner
SRZN
1Y +110.8% vs -1.0% ยท 52W Pos 63% vs 22%
Options & Structure Winner
SRZN
CONSOLIDATION (13th %ile IV) vs UNCLASSIFIED (N/A IV)
SRZN
NASDAQ
Surrozen, Inc. Common
Biological Products, (No Disgnostic Substances)
$28.46
-7.21% 1D
Market Cap
$642.7M
1M Return
+10.52%
1Y Return
+110.81%
Forward P/E
N/M
Unified AI Score
36.0 / 100
SELL
Tech 15.0
Fund 42.0
Flow 65.0
Mom 50.0
MTNB
NYSE American
Matinas BioPharma Holdings, Inc.
Pharmaceutical Preparations
$0.80
-1.26% 1D
Market Cap
$902,069
1M Return
-53.22%
1Y Return
-1.01%
Forward P/E
N/M
Unified AI Score
52.8 / 100
HOLD
Tech 53.0
Fund 54.0
Flow 50.0
Mom 60.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
SRZN +110.81%
MTNB -1.01%
Spread: +111.82 pp (SRZN Lead)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | SRZN Revenue | MTNB Revenue | SRZN Op. Margin | MTNB Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2018 | N/A | $0M | N/A | -12230.9% | MTNB |
| FY2019 | N/A | $0M | N/A | -21067.4% | MTNB |
| FY2020 | N/A | $0M | N/A | -15288.4% | MTNB |
| FY2021 | N/A | $0M | N/A | -74954.5% | MTNB |
| FY2022 | $10M | $0M | -354.7% | -771.3% | SRZN |
| FY2023 | N/A | $0M | N/A | -2168.4% | MTNB |
| FY2024 | $10M | N/A | -239.7% | N/A | SRZN |
| FY2025 | $0M | N/A | -1210.6% | N/A | SRZN |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | SRZN | MTNB | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $642.7M | $902,069 | Larger Scale | SRZN |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | +408.6% | -100.0% | Higher Growth | SRZN |
| Operating Margin (TTM) Profitability | -485.4% | 0.0% | Higher Margin | MTNB |
| Net Profit Margin Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Return on Equity (ROE) Capital Efficiency | -62.8% | -147.5% | Higher ROE | SRZN |
| 52-Week Range Position Momentum | 63% ($13โ$38) | 22% ($0โ$3) | Stronger Trend | SRZN |
| Beta / 30D Volatility Risk Regime | 1.29ฮฒ ยท 73% Vol | -6.35ฮฒ ยท 138% Vol | Lower Realized Risk | SRZN |
| Unified Institutional Score Composite Signal | 36.0 / 100 (SELL) | 52.8 / 100 (HOLD) | Higher Composite | MTNB |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full SRZN vs MTNB Buy Guide
SRZN
CONSOLIDATION
41d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
13th %ile
IV Regime
Compressed (<25th %ile)
MTNB
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither SRZN nor MTNB registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.